Art
J-GLOBAL ID:200902266120470649   Reference number:06A0423156

New Strategies in Chronic Myeloid Leukemia

慢性骨髄性白血病に対する新しい治療法
Author (2):
Material:
Volume: 83  Issue:Page: 289-293  Publication year: May. 15, 2006 
JST Material Number: F0888A  ISSN: 0925-5710  CODEN: IJHEEY  Document type: Article
Article type: 解説  Country of issue: Germany, Federal Republic of (DEU)  Language: ENGLISH (EN)
Thesaurus term:
Thesaurus term/Semi thesaurus term
Keywords indexed to the article.
All keywords is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.
,...
Semi thesaurus term:
Thesaurus term/Semi thesaurus term
Keywords indexed to the article.
All keywords is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.
,...
   To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=06A0423156&from=J-GLOBAL&jstjournalNo=F0888A") }}
JST classification (3):
JST classification
Category name(code) classified by JST.
Clinical application of antitumor(=antineoplastic)drugs  ,  Blood cell tumors(=neoplasms)  ,  Basic research of enzyme preparations and enzyme inhibitor preparations 
Reference (44):
  • O'BRIEN, SG. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003, 348, 994-1004
  • CORBIN, AS. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 2003, 101, 4611-4614
  • DONATO, NJ. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 2004, 64, 672-677
  • WEISBERG, E. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005, 7, 129-141
  • KANTARJIAN, H. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant bcr-abl positive chronic myeloid leukemia (CML). J Clin Oncol. 2005, 16, 195s
more...
Terms in the title (2):
Terms in the title
Keywords automatically extracted from the title.

Return to Previous Page